Evergreen Deception: How Big Pharma's Patent Gaming Keeps Generic Drugs Off Shelves and Patients in Crisis

The Drug That Should Cost $30 — and Why It Costs $300

In 2023, the list price of a monthly supply of a widely prescribed insulin analog in the United States was, depending on the formulation and pharmacy, between $250 and $500. The same drug, manufactured by the same company, sold for under $30 in Canada. The molecule had not changed. The manufacturing process had not changed. What had changed was the patent portfolio surrounding it — a thicket of secondary and tertiary intellectual property protections, layered over decades, that kept lower-cost generic competitors from reaching American pharmacy shelves.

This is evergreening: the pharmaceutical industry's most sophisticated and most legally laundered form of market manipulation. It is not a fringe practice. It is standard operating procedure. And it operates with the active participation of a regulatory system that was designed, at least in part, to enable it.

How Evergreening Works — and Why It's So Hard to Stop

The original logic of pharmaceutical patents is defensible in principle. Drug development is expensive and risky. A period of market exclusivity allows manufacturers to recoup research costs and generate the profit that theoretically incentivizes future innovation. The standard patent term is 20 years from the date of filing, after which generic manufacturers can produce and sell the same compound at competitive prices.

Evergreening subverts this logic without technically violating it. As a primary patent approaches expiration, manufacturers file new patent claims on secondary features of the same drug: a new delivery mechanism, a slightly modified dosage form, a new coating, a new salt formulation, a new method of administration. These modifications are, in most cases, clinically trivial — they do not meaningfully improve the drug's therapeutic effect. But they restart the patent clock, often by another 10 to 20 years, and each new patent provides grounds for litigation against generic manufacturers attempting to enter the market.

The data on the scale of this practice is striking. A 2018 study published in PLOS Medicine examined the 12 best-selling drugs in the United States and found that manufacturers held an average of 38 patents per drug — with some products carrying more than 100 patents. AbbVie's Humira, the world's best-selling drug for much of the past decade, accumulated more than 130 patents, allowing the company to maintain its U.S. monopoly years after European markets had opened to biosimilar competition. The result was a drug that cost American patients and insurers roughly $77,000 per year per patient, compared to a fraction of that price abroad.

Pay-for-Delay: When Monopolies Pay Competitors to Stay Away

Evergreening does not operate alone. It is frequently paired with a second legal maneuver known as a pay-for-delay agreement — sometimes called a reverse payment settlement — in which a brand-name manufacturer, facing a patent challenge from a generic competitor, pays that competitor a substantial sum to drop the lawsuit and delay market entry.

The economics of these arrangements are straightforward: if a brand-name drug generates $3 billion in annual revenue, paying a generic challenger $200 million to stay out of the market for three additional years is an extraordinarily profitable transaction for both parties. The loser is everyone else — patients, employers, insurers, and taxpayers funding government health programs.

The Supreme Court's 2013 ruling in FTC v. Actavis held that pay-for-delay agreements could, under some circumstances, violate antitrust law — a significant but incomplete victory for reformers. The ruling did not ban the practice outright. It required a case-by-case rule-of-reason analysis, a standard that has proven difficult for the Federal Trade Commission to apply consistently and that has not meaningfully curtailed the frequency of these agreements. The FTC has estimated that pay-for-delay deals cost American consumers approximately $3.5 billion per year in higher drug prices.

Real People, Real Consequences

The human cost of this system is not evenly distributed. It falls most heavily on patients with chronic conditions requiring expensive brand-name medications — people with diabetes, cancer, multiple sclerosis, rheumatoid arthritis, and HIV. It falls on the uninsured and the underinsured. It falls on the elderly managing multiple prescriptions on fixed incomes. And it falls on the millions of Americans who, according to a 2023 Kaiser Family Foundation poll, report rationing prescribed medication because they cannot afford the full dose.

Rationing insulin is not a minor inconvenience. It is a life-threatening practice that has been directly linked to diabetic emergencies and deaths. Rationing cancer medication can mean the difference between a treatment protocol that works and one that fails. These are not edge cases. They are the predictable, documented consequences of a pricing structure that pharmaceutical manufacturers have deliberately engineered and that the regulatory system has failed to dismantle.

The Legislative Graveyard

Bipartisan drug pricing legislation is not new. Bills to restrict pay-for-delay agreements, accelerate generic approval, and cap out-of-pocket costs have passed the House in various forms and attracted co-sponsors from both parties in the Senate. The Inflation Reduction Act of 2022 represented a partial step forward, granting Medicare the authority to negotiate prices on a limited number of drugs — a provision that the pharmaceutical industry immediately challenged in court and that applies to a fraction of the drugs driving costs.

Broader reform consistently dies before reaching a Senate floor vote, killed by a combination of pharmaceutical industry lobbying — which spent more than $370 million on federal lobbying in 2022 alone, according to OpenSecrets — and the structural dynamics of a chamber where a determined minority can indefinitely delay legislation. The industry's campaign contributions flow to members of both parties, and its influence over the legislative calendar is, by any honest accounting, substantial.

The strongest counterargument from the industry is that patent protections and premium pricing fund the research and development pipeline that produces breakthrough drugs. This argument has genuine merit at the margins. But it does not withstand scrutiny as a defense of evergreening specifically. Filing a new patent on a modified pill coating that provides no clinical benefit to patients is not research. It is rent extraction, dressed in the language of innovation.

What a Different System Looks Like

Every other wealthy democracy has mechanisms that the United States lacks: robust government price negotiation, reference pricing tied to international benchmarks, and regulatory bodies empowered to reject evergreening patents that do not demonstrate meaningful clinical improvement. The result is that patients in Germany, France, Australia, and Canada pay a fraction of what Americans pay for the same compounds.

The United States is not incapable of building such mechanisms. It is unwilling — or rather, its legislative institutions have been made unwilling by an industry that has spent decades and billions of dollars ensuring that the gap between what reform requires and what Congress delivers remains unbridgeable.

For the patient rationing their medication at the kitchen table, the distance between what is possible and what their government has chosen to provide is not a policy nuance. It is a daily emergency — and it is one that their elected representatives have the power, if not yet the political will, to end.